Adverse Effects Under Th2 Biologics (Dupilumab and Tezepelumab) in a Patient with Severe Asthma and Atopic Dermatitis

被引：1
|
作者：
Suhling, Hendrik [1 ]
Hinze, Christopher Alexander [1 ]
Welte, Tobias [1 ]
Werfel, Thomas [2 ]
Traidl, Stephan [2 ]
机构：
[1] Hannover Med Sch, Dept Resp Med & Infect Dis, Hannover, Germany
[2] Hannover Med Sch, Dept Dermatol & Allergy, Hannover, Germany
来源：
RESPIRATION | 2023年 / 102卷 / 12期
关键词：
Severe asthma; Dupilumab; Tezepelumab; Side effects;
D O I：
10.1159/000534924
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Introduction: This is the first report of a patient with severe asthma and atopic dermatitis that developed local perioral skin infection which onset coincided with the patient's treatment with dupilumab (candida albicans) and later with tezepelumab (microscopic detection of yeast). Case Presentation: Besides moderate headache, macular exanthema was found after administration of tezepelumab, which was subsequently accompanied by a worsening of symptoms upon reexposure to the treatment. Both sensations needed multidisciplinary treatment and both antibody therapies were stopped.
引用
收藏
页码：1016 / 1019
页数：4
相关论文
共 50 条
  • [41] Prevalence of IgE-mediated allergy and evaluation of Th1/Th2 cytokine profiles in patients with severe bronchial asthma
    Rogala, Barbara
    Bozek, Andrzej
    Gluck, Joanna
    Jarzab, Jerzy
    POSTEPY DERMATOLOGII I ALERGOLOGII, 2015, 32 (04): : 274 - 280
  • [42] Mesenchymal Stem Cells Suppress Severe Asthma by Directly Regulating Th2 Cells and Type 2 Innate Lymphoid Cells
    Shin, Jae Woo
    Ryu, Seungwon
    Ham, Jongho
    Jung, Keehoon
    Lee, Sangho
    Chung, Doo Hyun
    Kang, Hye-Ryun
    Kim, Hye Young
    MOLECULES AND CELLS, 2021, 44 (08) : 580 - 590
  • [43] Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab Versus Dupilumab in Moderate-to-Severe Atopic Dermatitis'
    Bastian, Mike
    Freemantle, Nick
    Rossi, Ana B.
    Shumel, Brad
    Le Bagousse, Gaelle Bego
    Wang, Zhixiao
    Xu, Yingxin
    Guyot, Patricia
    DERMATOLOGY AND THERAPY, 2024, 14 (03) : 819 - 821
  • [44] Chlorophyll a and novel synthetic derivatives alleviate atopic dermatitis by suppressing Th2 cell differentiation via IL-4 receptor modulation
    Kang, Koon Mook
    Han, Jung-Hyun
    Kim, Kyeong Seok
    Kim, Eun Kyung
    Shin, Youna
    Park, Jae Hyeon
    Kim, Hyeon
    Kim, Na Yoon
    Kim, Yoon Gyoon
    Kim, Hyunjun
    Park, Hyunjin
    Kim, Young-Mi
    Kee, Seung-Jung
    Kim, Seong-Jin
    Kim, Hyung Sik
    Kim, Yong-Chul
    CLINICAL IMMUNOLOGY, 2024, 258
  • [45] The effect of dupilumab on caregiver- and patient-reported outcomes in young children with moderate-to-severe atopic dermatitis: Results from a placebo- controlled, phase 3 study
    Paller, Amy S.
    Silverberg, Jonathan I.
    Simpson, Eric L.
    Cork, Michael J.
    Arkwright, Peter D.
    Chen, Zhen
    Bansal, Ashish
    Prescilla, Randy
    Wang, Zhixiao
    Marco, Ainara R.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2025, 92 (01) : 116 - 126
  • [46] Facial dermatoses and use of protective mask during Covid-19 pandemic: A clinical and psychological evaluation in patients affected by moderate-severe atopic dermatitis under treatment with dupilumab
    Vanessa, Mazzoletti
    Elia, Esposto
    Federica, Veronese
    Edoardo, Cammarata
    Chiara, Airoldi
    Francesca, Graziola
    Paola, Savoia
    DERMATOLOGIC THERAPY, 2022, 35 (07)
  • [47] Use of dual biologic therapy targeting the Th2 and Th17 axes simultaneously to treat patients with atopic dermatitis and concomitant psoriasis, psoriatic arthritis, or inflammatory bowel disease
    Hren, Mary Grace
    Guenin, Sophie
    Khattri, Saakshi
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 91 (01) : 138 - 140
  • [48] Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD)
    Simpson, Eric L.
    Gadkari, Abhijit
    Worm, Margitta
    Soong, Weily
    Blauvelt, Andrew
    Eckert, Laurent
    Wu, Richard
    Ardeleanu, Marius
    Graham, Neil M. H.
    Pirozzi, Gianluca
    Sutherland, E. Rand
    Mastey, Vera
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 75 (03) : 506 - 515
  • [49] Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registry
    Zhang, Junfen
    Boesjes, Celeste M.
    Loman, Laura
    Kamphuis, Esme
    Romeijn, Margreet L. E.
    Spekhorst, Lotte S.
    Haeck, Inge
    van der Gang, Lian F.
    Dekkers, Coco C.
    van der Rijst, Lisa P.
    Oosting, Albert J.
    van Lumig, Paula
    Nes, Anneke M. T. van Lynden-van
    Tupker, Ron A.
    Nijssen, Annieke
    Flinterman, Annebeth
    Politiek, Klaziena
    Touwslager, Wouter R. H.
    Christoffers, Wianda A.
    Stewart, Shiarra M.
    Kamsteeg, Marijke
    de Graaf, Marlies
    de Bruin-Weller, Marjolein S.
    Schuttelaar, Marie-Louise A.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 91 (02) : 300 - 311
  • [50] Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2)
    Thaci, Diamant
    Simpson, Eric L.
    Deleuran, Mette
    Kataoka, Yoko
    Chen, Zhen
    Gadkari, Abhijit
    Eckert, Laurent
    Akinlade, Bolanle
    Graham, Neil M. H.
    Pirozzi, Gianluca
    Ardeleanu, Marius
    JOURNAL OF DERMATOLOGICAL SCIENCE, 2019, 94 (02) : 266 - 275
12345